RT-GLP3
30mgTriple-receptor research peptide (GLP-1/GIP/glucagon). Lyophilised vial for reconstitution.
RM 290.00
Out of stock
- Independently testedCertificate per batch
- Lyophilised & sealedSterile single vial
- Ships from MalaysiaPlain packaging, next workday dispatch
TR-GLP2
40mg
Dual GIP/GLP-1 receptor agonist research peptide. Lyophilised vial for reconstitution.
RM 320.00
1
Included free with every order
- Bacteriostatic waterThe solvent this vial needs — nothing else to buy
- Premium reconstitution tool set3 mL reconstitution syringe, 50IU syringes, alcohol swabs
TR-GLP2 is our coded name for Tirzepatide, a dual GIP/GLP-1 receptor agonist and one of the most extensively studied incretin-based compounds in current literature, including multiple Phase 3 randomised trials (the SURPASS programme). Published research describes its effects on glycaemic control and body weight relative to single-receptor GLP-1 agonists. This vial ships lyophilised for reconstitution, strictly for laboratory and research use.
Studied for
- Dual agonism at GIP and GLP-1 receptors in metabolic research
- Glycaemic-control research versus single-receptor GLP-1 agonists (SURPASS trial programme)
- Body-composition and weight-regulation research
A typical dose referenced in published research literature is 5–15 mg per week — the range used across the SURPASS trial programme.
What is in the vial
| Component | Mass | Research profile | Profile |
|---|---|---|---|
| Tirzepatide | 40 mg | Dual GIP/GLP-1 receptor agonist research | Wiki → |
Third-party testing
A manufacturer's own purity figure is not independent verification. Every batch we sell is tested by an independent laboratory before it is offered.
Certificate of Analysis is on file for every batch and available on request.
What the literature actually says
Independent published research on this material. We link to the source rather than summarising it.
- 2022Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction — Cardiovasc Diabetol
- 2021Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1) — Lancet
- 2024Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists — Front Endocrinol
What this blend has not been shown to do
The trials referenced above enrolled adults with type 2 diabetes or obesity under clinical supervision. They say nothing about outcomes in an unsupervised research context, and none establish long-term effects beyond each trial’s follow-up window.
Storage
| Unreconstituted powder | |
|---|---|
| −20 °C | 24 months |
| 2–8 °C | 6 months |
| Room temperature | 30 days |
| Reconstituted solution | |
| 2–8 °C | 30 days |
| +15 °C | Caution — only 7 days |
| +30 °C | Caution — only 24 hours |
| Below 0 °C | Do not use. Discard |
Never freeze a reconstituted vial — a frozen solution is spoiled.
Reconstitution
- Let the vial reach room temperature before opening — cold glass pulls condensation.
- Swab the stopper. Use bacteriostatic water, or acetic acid where the compound calls for it.
- Run the solvent slowly down the inside wall, never onto the powder.
- Swirl gently. Do not shake — agitation shears the peptide.
- Let it stand 5–10 minutes until fully in solution before drawing.
- Refrigerate at 2–8 °C immediately once reconstituted.
- Never freeze it. Below 0 °C the solution is spoiled — discard the vial.
Work out your draw
Our calculator opens pre-filled for a 40mg vial — enter your target dose and it returns the draw in units.
Open the calculatorFrequently paired with